CureVac Reports Data From Phase 2b/3 Trial Of COVID-19 Vaccine; Showed Efficacy Of 53% Against Disease Of Any Severity, Efficacy Of 77% Against Moderate And Severe Disease, Full Protection Against Hospitalization Or Death
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
·
Unique pivotal study conducted in
